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Amplification or mutations in members of the epidermal growth factor receptor family, 
such as HER2, have been identified in several human diseases. In particular, mutations in the 
intracellular kinase domain have been identified in breast, colon, and lung cancers. The Cancer 
Genome Atlas has identified HER2 mutations or gene amplification in seven percent of colon 
cancer patients. These mutations are well known to promote enhanced cell growth and 
transformation of colon cancer cell lines. Previous studies have found HER2 mutations to confer 
anchorage independent growth and activation of downstream signaling pathways such as MAPK. 
Although HER2 mutations have been extensively characterized using cell line overexpression 
models, the role of HER2 alterations on tumorigenesis, particularly in the gastrointestinal tract, 
has not been studied. In this thesis, the role of an activating HER2 mutation, V777L, was 
examined using small intestinal organoids, a three-dimensional culture model. Additionally, we 
also sought to explore the cooperative role of both HER2 and APC mutations. Using this model, 
we showed distinct morphological changes in intestinal organoids upon expression of either 
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HER2 or APC alone, or in combination. Furthermore, in vivo expression of HER2V777L driven by 
the Lgr5-Cre recombinase showed increased intestinal hyperplasia throughout the small intestine 
and the loss of distinct intestinal cell populations. This work is the first characterization of an 
activating HER2 mutation in the intestine using a transgenic mouse model and a three-
dimensional culture model. Lastly, we show that in vitro expression of oncogenic mutations such 
as KRAS in HER2 mutated colon cancer cell lines confers reduced sensitivity to a HER2-
targeted therapeutic, neratinib, which further illustrates the impact of multiple oncogenic 
mutations on cell growth. Taken together, we illustrate the role of HER2 and co-occurring 
mutations on the intestinal epithelium as well as the effect of HER2 and KRAS co-occurring 










Chapter 1: Introduction 
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1.1 Summary of EGFR family of receptor tyrosine kinases 
The epidermal growth factor receptor (EGFR) is a member of a receptor tyrosine kinase family 
comprised of the HER2, HER3, and HER4 receptor tyrosine kinases (1). In particular, epidermal 
growth factor, was first discovered by Stanley Cohen as a peptide that accelerated eyelid opening 
in newborn mice (2). The structure of these receptor tyrosine kinases includes a cytoplasmic-
ligand binding domain, a transmembrane region, and an intracellular region containing the kinase 
domain (Figure 1.1A). Activation of these receptors is conferred by ligand-mediated 
dimerization of EGFR family members (3). Specifically, ligand binding to subdomains I and III 
triggers a conformational change from the tethered to extended conformation allowing the 
dimerization arm in subdomain II to be exposed for interaction with other EGFR family 
members (4) (Figure 1.1B). Following dimerization, kinase domain activation facilitates 
phosphorylation of the cytoplasmic tail of both receptors and allows for binding of effector 
proteins for downstream signaling pathway activation to promote enhanced cell growth, 
proliferation, and cell-cycle progression (5).  
EGFR, has six known ligands including EGF, TGF-α, amphiregulin, epiregulin, as well as others 
(6). Neuregulins, such as NRG1 and NRG2 bind to HER3 and HER4, and NRG3 and NRG4 
exclusively bind to HER4 (7). In contrast, no known ligand has been identified for HER2 (8). 
Additionally, HER3 has minimal kinase activity in relation to the other EGFR family members 
and forms hetero-dimers with other EGFR family members, such as HER2, to mediate 
intracellular signaling (9). In addition to activation in a ligand-dependent manner, EGFR family 
members can also be activated via overexpression or mutation in a ligand-independent manner. 
Mutation or overexpression of EGFR family members has also been reported in several cancers, 











Figure 1.1 Structure of the EGFR family of Receptor Tyrosine Kinases. This figure is 
adapted from Croucher, D., 2016 (4). 
1.2 Role and significance of EGFR family members in cancer 
Human tumors have been found to overexpress EGFR and other related family members, and 
expression of these receptors often results in a more aggressive disease phenotype (12). In 
addition, gene amplification, kinase domain mutations, and in-frame deletions of EGFR family 
members have also been identified in several cancer types (13-15). These alterations promote 
constitutive activation of downstream signaling pathways and confer enhanced tumor growth and 
development. For example, in non-small cell lung cancer (NSCLC), point mutations in the kinase 
domain of EGFR, such as L858R (38%) and in-frame deletions or insertions in exon 20 (6%) 
have been identified (16-17). Mutations in the kinase domain have also been shown to promote 
oncogenic properties in vitro and confer resistance to EGFR tyrosine kinase inhibitors (18-19). 
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Similarly, HER2 kinase domain mutations, such as in-frame exon 20 insertions, were identified 
in 1-4% of NSCLCs (20). The HER2 G776YVMA insertion mutation, for example, enhanced 
tyrosine kinase activity and conferred resistance to EGFR tyrosine kinase inhibitors using cell 
culture based assays (21). In addition, to somatic mutations, gene amplification of EGFR or 
HER2 occurs in 62% and ~30% of NSCLCs, respectively (22-23). Gene amplification of EGFR 
has also been found to result in response to EGFR tyrosine kinase inhibitors (24). In summary, 
over-expression and mutation of EGFR and HER2 in NSCLCs serve to hyper-activate down-
stream signaling pathways and confer resistance to targeted therapies. 
EGFR family members such as HER2 and HER3 are also over-expressed in other cancer types. 
Specifically, HER2 and HER3 are over-expressed in 20% and 50-70% of breast cancer cases, 
respectively (25-26). HER2 and HER3 form a potent heterodimer and mediate downstream 
signaling to enhance tumor growth and development. Additionally, overexpression of HER2 and 
HER3 are associated with worse clinical outcomes and reduced overall survival in breast cancer 
patients (27-28). HER2 amplified breast cancers, however, have increased sensitivity to targeted 
chemotherapeutics, such as Herceptin. In addition to breast cancer, HER2, HER3, and other 
EGFR family members are widely overexpressed in ovarian, prostate, bladder, gastric, and 
colorectal cancers and are associated with poor disease outcomes (29-32).  
1.3 Prevalence and role of HER2 mutations in colon cancer 
The Cancer Genome Atlas (TCGA) has identified somatic mutations or gene amplification of 
HER2 in 7% of colorectal patients (33). Several of these mutations are identical to those 
identified in breast cancer patients. For example, the HER2 V842I and V777L mutations have 
been identified in both breast and colorectal cancer. These mutations were found to cluster in 
5 
 
several hotspots throughout the extracellular domain, at residues 309-310, and 755-781 in the 
kinase domain (Figure 1.2). Previous characterization of these mutations in breast and lung 
cancer has revealed that these mutations enhance downstream signaling pathways and confer 





Figure 1.2 Schematic of HER2 somatic mutations in 12 colon cancer patients. This figure is 
adapted from Kavuri, S. (2015). 
1.4 In vitro characterization of HER2 activating mutations 
Several studies have explored the role of HER2 mutations on cell growth and proliferation using 
colon or breast cell lines. Specifically, overexpression of wild-type HER2 and five different 
HER2 mutations (HER2 V777L, V842I, L755S, L866M, and S310F) into immortalized colon 
epithelial cells were shown to increase phosphorylation of HER2, activate downstream signaling 
pathways, and enhance colony formation in soft-agar assays (37). In particular, the L755S, 
V777L, and L866M mutations increased the number of colonies in soft-agar, whereas, the V842I 
mutation produced the least number of colonies in this assay. The strength and observed 
phenotype of these mutations in vitro can therefore vary depending on the location and amino 
acid change of each mutation. Overall, these mutations were found to be activating mutations 
using in vitro experimental assays.  
Similar studies of HER2 mutations in non-transformed mammary epithelial cells, MCF10A, also 




knock-in of a single copy of these mutations using adeno-associated virus in breast epithelial cell 
lines (MCF-10A and MCF7) only identified the HER2 V777L mutation to be transforming, 
indicating that the expression level of HER2 in cell lines can influence observed phenotypes 
(35).  
Due to the striking in vitro phenotype of these mutations, biological assays have also been 
utilized to further determine how HER2 mutations can confer different biological effects. For 
example, in vitro kinase assays have been utilized to compare the strengths of various mutations. 
Using these assays, the HER2 V777L, D769H, and V842I mutations were found to have higher 
activity relative to wild-type (36). Interestingly, among the three mutations that were tested, the 
V777L mutation had 20 fold higher activity compared to the V842I mutation, which only had 3 
fold-higher activity relative to WT. These differences in kinase activity underscore important 
distinctions between the different kinase mutations. Additionally, the strength of these mutations 
has also been found to have distinct effects on sensitivity to HER2 based therapeutics. 
1.5 Pre-clinical data on HER2 mutations and inhibitor sensitivity 
Studies of the activating HER2 mutations in breast cancer cell lines determined that several 
HER2 mutations are sensitive to dual HER2/EGFR tyrosine kinase inhibitors, such as neratinib 
(36). Unlike monoclonal antibodies, such as trastuzumab that bind to the extracellular domain of 
HER2, tyrosine kinase inhibitors block kinase activity and subsequent phosphorylation. 
However, the HER2 L755S mutation was found to be resistant to another HER2 TKI, lapatinib. 
The lack of sensitivity to this therapeutic is due to the proximity of the mutation to the binding 
site of the drug (38). Similarly, the introduction of HER2 mutations in colon cancer cell lines 
with intrinsic sensitivity to EGFR monoclonal antibodies, such as cetuximab, conferred 
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resistance to these therapies (37). Although these cell lines were resistant to EGFR targeted 
therapy alone, these cell lines were sensitive to neratinib.  
Studies by Kloth et al have also explored HER2 mutations and their sensitivity to HER2 targeted 
therapy using colon cancer cell lines with endogenous HER2 mutations. Specifically, the colon 
cancer cell lines, CW-2 and CCK-81, cell lines, which express the endogenous HER2 L755S and 
L720P mutations, respectively, have also been shown to be sensitive to afatinib in the nanomolar 
range (39). The CW-2 cell line, however, is resistant to lapatinib due to the L755S mutation, as 
mentioned previously. Bertotti et al has also identified genetic alterations in EGFR family 
members, such as HER2, to be a mechanism of resistance to EGFR therapeutics, further 
supporting the ideal that alterations in HER2 can alter sensitivity to antibodies commonly used to 
treat colon cancer patients (40). 
As mentioned previously, EGFR targeted therapies are often commonly used to treat metastatic 
colorectal cancer patients. However, common mechanisms of resistance to EGFR therapeutics 
include activation of downstream signaling effectors such as KRAS, PIK3CA, BRAF, etc (41). 
Mutations in the Ras/Raf/ MAPK pathway lead to hyper-activation of cell signaling pathways, 
rendering therapeutics targeting EGFR, such as cetuximab, ineffective. Additionally, a basket 
trial studying HER2 mutations across multiple tumor types also determined that, unlike HER2 
mutated breast cancer patients, colorectal cancer patients possessing HER2 mutations are also 
resistant to neratinib (42), suggesting that multiple mechanisms could be responsible for the lack 
of response to therapy.  
1.6 Role of EGFR family members on intestinal homeostasis  
In addition to their role in cancer, EGFR family members also maintain homeostasis of the 
intestinal epithelium. The intestinal epithelium is comprised of crypts of Lieberkuhn and villi, 
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which function in the absorption of food. The crypts contain intestinal stem cells and Paneth cells 
that are interspersed between stem cells at the base of the crypt (Figure 1.3). Crypt-base 
columnar stem cells reside at the base of the crypt and give to transit-amplifying cells. The 
transit-amplifying cells terminally differentiate into several epithelial cell types, such as goblet 
cells that secrete mucus and are located along the villus (43). Other differentiated cell types 
include absorptive enterocytes, chemosensory tuft cells, and hormone-releasing enteroendocrine 
cells. Paneth cells, however, migrate downward 
towards the crypt base and produce Wnt, EGF and 
other growth factors for maintenance of the stem 
cell niche (44). Proliferation is also typically 
restricted to the crypt and differentiation occurs 
along the villus.  
 
Additionally, expression of growth factor receptors control intestinal cell proliferation, growth, 
and wound-healing (45-48). EGFR signaling in the gut is responsible for regulating growth, 
migration, survival, intestinal development, and serves as a gastrointestinal protective factor via 
binding to EGFR (49-53). Previous studies have also determined that EGF expression enhances 
villus height and crypt depth, implicating a role for EGF on intestinal growth and development 
(54). Due to the role of EGFR on intestinal barrier protection and wound-healing, loss of EGFR-
mediated signaling often results in inflammatory disorders such as colitis and several studies 
have explored the role of EGFR family members on the intestinal epithelium following injury.  
Figure 1.3 Crypt-villus structure and intestinal cell types. This figure is adapted from 
Murray, E. (2020-CMGH Submission) 
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Studies exploring the functional role of EGFR have identified a protective role for EGFR 
signaling in spontaneous colitis models (55). EGFR inactivation in these models resulted in 
accelerated colitis, suggesting that EGFR plays a role in the initiation and progression of colitis 
associated disorders. In contrast, studies of the role of HER2 on the intestinal epithelium are 
somewhat limited due to embryonic lethal cardiac defects caused by deletion of HER2 (56). 
Epithelial expression of HER2 is required for short-term recovery from colitis and knockout of 
HER2 in intestinal epithelial cells results in hyper-proliferation and apoptosis (57). Similarly, 
knockout of HER3 also produces embryonic lethal cardiac defects, however HER3 expression 
has also been found to play a protective role in the intestinal epithelium following injury (57). 
The role of HER4 on the intestinal epithelium, however, is less well characterized. Expression of 
HER4 in the intestinal epithelium by NRG4 administration hyperactivates the PI3K/Akt pathway 
and protects the intestinal epithelium from DSS-mediated colitis (58).  
1.7 Role of EGFR family members in colorectal tumorigenesis 
Several studies have also explored the role of EGFR family members on colorectal 
tumorigenesis. EGFR, HER2, and HER3 are commonly over-expressed in intestinal cancers (59-
61). In particular, EGFR expression is increased in colonic pre-cancerous lesions and tumors 
(62-63). Animal models exploring the role of EGFR on tumor initiation and development have 
determined that inactivation of the EGFR kinase domain using Egfrwa2 mice resulted in a 90% 
reduction of intestinal polyp formation, suggesting that EGFR is required for intestinal tumor 
development (64). In contrast, HER2 overexpression models for colon cancer have not been 
developed outside of our laboratory. Models exploring the role of HER2 overexpression on 
breast epithelium, however, have determined that overexpression of wild-type HER2 (MMTV-
neu) confers hyperplasia and oncogenic transformation of the epithelium (65). Lastly, intestine 
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specific deletion of HER3 also results in a near complete absence of intestinal tumors using the 
Apcmin mouse model, which develops intestinal tumors due to loss of the Apc gene, suggesting 
that HER3 plays a crucial role in tumor initiation (66).  
1.8 Summary of existing colon cancer mouse models 
Several mouse models for colorectal cancer have been developed that explore the role of co-
occurring mutations, such as KRAS and APC on tumorigenesis. KRAS mutations, for example, 
are present in 40-50% of colorectal adenomas and carcinomas, whereas mutations in APC are 
present in 60-80% of colorectal carcinomas (67-68). For example, studies examining the role of 
KRAS and APC mutations on tumorigenesis have determined that expression of KRAS alone did 
not initiate adenoma development, however, expression of KRAS and APC mutations together 
accelerated tumorigenesis (69). Mechanisms underlying this phenotype were attributed to 
activation of the Mapk signaling pathway and increased expression of Wnt/B-catenin target 
genes.  
Other studies have examined the role of several colorectal cancer driver genes, such as APC, 
KRAS, TRP53, and TGFBR2 on malignant progression of colon cancer. Using mouse models 
expressing APCΔ716, KRASG12D, TRP53R270H, and TGFR2-/- in various combinations, the effect 
of each mutation on polyp development was determined. Specifically, the combination of APC 
and KRAS mutations lead to an increase in the number of small polyps relative to each mutation 
alone (70). Additionally, KRAS activation also promoted formation of liver metastases when 
combined with APC and TGFBR2 mutations (70). Similarly, studies analyzing APC, KRAS, and 
TP53 on colorectal cancer metastasis, identified a crucial role for KRAS in driving metastasis via 
up-regulation of TGF-β signaling (71). Taken together, these studies illustrate the role of several 
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colorectal cancer driver genes on adenoma to carcinoma progression and metastasis and the 
underlying signaling pathways involved in transformation.  
1.9 Overview of 3D intestinal organoid culture models 
Small intestinal epithelial cells can be cultured in Matrigel to form three-dimensional structures, 
named organoids, which morphologically resemble the crypt and villus of the small intestinal 
epithelium. These organoids self-organize into budded structures, resembling the crypts, and 
contain a central lumen lined by the villus domain (Figure 1.4). Studies by Sato et al. have 
established culture conditions for mouse-derived organoid cultures that include growth factors 
needed for survival, such as EGF, Noggin, R-spondin, etc (72). EGF enhances proliferation in 
organoid cultures, Noggin inhibits bone morphogenic protein to enhance crypt development, and 
R-spondin induces crypt hyperplasia (73-75). Additionally, lineage tracing analysis of crypts 
isolated from Lgr5-EGFP-ires-CreERT2 mice revealed that single Lgr5 positive cells can 
generate crypt-villus structures in vitro (76). Organoids derived from single stem cells also 
contain all of the differentiated cell types found within the intestinal epithelium such as Paneth, 
goblet, and enteroendocrine cells. Lastly, studies exploring the role of EGFR family members on 
organoid morphology have determined that loss of Lrig, a negative regulator of EGFR signaling, 
results in growth-factor independence in organoid cultures grown in media lacking EGF (77). As 
a result, intestinal organoid culture can be useful in determining the role of particular genetic 






 In conclusion, the role of EGFR family of receptor tyrosine kinases has been extensively 
characterized in several cancer types and their role in enhancing proliferation, cell growth, and 
migration has been well established. Additionally, EGFR family members play crucial roles in 
maintaining intestinal epithelial homeostasis and tumorigenesis. In particular, our lab and others 
are interested in the role of HER2, an EGFR family member, on colorectal cancer. In vitro 
characterization of HER2 mutations, such as HER2 V777L, has identified that HER2 mutations 
located throughout the kinase domain, are activating mutations that enhance MAPK downstream 
signaling pathways in colon cancer cell lines. Although HER2 mutations have been characterized 
in vitro, our knowledge of their role on intestinal epithelial homeostasis, crypt-villus architecture, 
and colorectal tumorigenesis remains sparse. In particular, studies exploring the role of the 
activating HER2 mutation, HER2V777L in vivo would allow us to better understand the 
developmental mechanisms underlying intestinal tumorigenesis and gain further insight into how  
intestinal cells, such as Paneth cells, are changed by expression of HER2V777L. In addition, the 
role of an activating HER2 mutation has not been previously characterized using a transgenic 
mouse model or an intestinal organoid model. As a result, the next two chapters of this thesis 
will address the following two questions that remain unanswered in the field: (1) What are the 
morphological changes associated with in vitro expression of HER2V777L alone or in combination 
with APC in intestinal organoids, (2) How does in vivo expression of HER2 and APC mutations 
impact intestinal epithelial proliferation, crypt-villus architecture, expression of secretory cells, 
and tumor formation? Lastly, the role of HER2 and co-occurring mutations on therapeutic 
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Mutations or amplification of HER2 has been identified in 7% of colorectal cancer (CRC) 
patients and are known to result in activation of downstream signaling pathways such as MAPK. 
In addition to HER2 mutations, colorectal cancer patients also possess co-occurring mutations in 
APC, a tumor suppressor gene highly mutated in CRC. Using an intestinal organoid model 
derived from a HER2V777L and APCmin double mutant mice, we determined that HER2V777L 
expression alone increased proliferation and activation of downstream signaling pathways. In 
contrast, the expression of both HER2 and APC mutations in the intestinal organoid model 
increased proliferation, conferred a distinct morphological phenotype, and activated Wnt-target 
genes. Our experiments provide novel characterization of HER2V777L expression on both 






Colorectal cancer (CRC) is initiated by the loss of a tumor suppressor gene, APC, and 
subsequent alterations in oncogenes such as KRAS, facilitate the adenoma to carcinoma 
transition (78). This step-wise model of tumorigenesis has been well described and several 
studies have shown the relevance of oncogenes in CRC disease development and progression to 
metastasis. APC mutations, for example, are present in 90% of colorectal cancer patients and are 
often the first “hit” that initiates the transition from the normal intestinal epithelium to an 
adenoma (68). Mutations in APC also hyper-activate Wnt signaling and disrupt intestinal 
homeostasis. Genetically engineered mouse models such as the APCmin mice, develop several 
small intestinal polyps, and have been extensively utilized to characterize the role of APC gene 
loss on CRC development (79-81). In addition to alterations in tumor suppressor genes, recent 
studies have also identified the presence of mutations or alterations in a receptor tyrosine kinase 
gene, HER2, in CRC patients.  
In vitro characterization of HER2 mutations has identified several activating mutations such as 
V777L, V842I, and L755S that promote anchorage independent growth and activate intracellular 
signaling pathways in colon cancer cell lines (37). Additionally, a recent basket trial of HER2 
and HER3 mutant cancers by Memorial Sloan Kettering demonstrated that HER2 mutant colon 
cancer patients possessed co-occurring mutations in APC (42). The prevalence of HER2 and 
APC mutations was also illustrated in studies by the Dana Farber Cancer Institute using 619 
colorectal cancer patients (82). Given the well-defined role of APC mutations in CRC 
progression and development, we reasoned that HER2 and co-occurring mutations in APC would 
hyper-activate downstream signaling pathways and induce changes in the intestinal epithelium 
relative to HER2 or APC mutations by themselves. Furthermore, the role of HER2 and co-
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occurring mutations on intestinal cell development has not been extensively characterized and 
could aid in the development of novel treatment options for HER2 mutated colon cancer patients. 
To study the effect of both HER2 and APC mutations on the intestinal epithelium and various 
intestinal cell types, we utilized an intestinal organoid model. Specifically, we utilized intestinal 
organoids derived from HER2V777L transgenic (Tg) and APCmin; HER2V777L Tg mice. Using the 
intestinal organoid model, we determined that expression of HER2V777L alone conferred 
increased budding and expression of HER2 and APC mutations, when combined, resulted in 
activation of Wnt signaling genes. Overall, we utilized the intestinal organoid model to illustrate 
the role of HER2V777L and additional genetic alterations on proliferation, organoid morphology, 













Intestinal crypt culture 
Isolation of crypts from the jejunum of HER2V777L Tg littermate mice were performed as 
described (72). Briefly, four to six centimeters of medial jejunum were isolated from HER2V777L 
Tg mice. The intestine was cut lengthwise and rinsed quickly in ice-cold PBS. Intestinal tissues 
were vortexed in cold PBS in a 50 mL conical tube to clean lumen contents. To loosen mucus, 
intestinal tissues were vortexed in 10 mL of calcium and magnesium free-Hank’s Balanced Salt 
Solution (CMF-HBSS) with 1 mM N-acetyl cysteine (NAC) for 15 seconds for a total of 2 
minutes in a 15 mL conical tube. Intestinal tissues were incubated with 10 mL of ice cold CMF-
HBSS containing 10 mM EDTA and 1 mM NAC on a rotator for 45 minutes. Following the 45 
minute incubation, the conical tube containing intestinal tissues was vortexed for 30 seconds 
(rest 30 seconds on ice) for 8 minutes total. The vortexed solution was then poured filtered using 
a 70 µm BD filter. Eluates were centrifuged for 1 min at 100 x g and the supernatant was 
removed. Intestinal crypts were resuspended in basal culture media and 10 uM ROCK inhibitor 
and spun at 100 x g for 2 minutes.  
Isolated intestinal crypts were embedded in Matrigel (BD Biosciences) and seeded in 6-well 
plates. The cells were overlaid with 2 mL/well basal culture medium (advanced Dulbecco’s 
modified Eagle medium/F12 supplemented with penicillin/streptomycin, 10 mmol/L HEPES, 
Glutamax, 1 × N2, 1 × B27 [all from Thermo Fisher Scientific], and containing EGF (Sigma), 
noggin, and Rspo1 (Noggin and R-spondin conditioned media were a gift from Blair Madison). 
Individual polyps from the distal small intestine of APCmin; Her2 Tg were picked and re-
suspended in Hanks Balanced Salt Solution (HBSS-Invitrogen) and incubated with 0.5 M EDTA 
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(Sigma) for 30 minutes at 4°C. Crypts were centrifuged at 500 x g for 45 seconds and the pellet 
was re-suspended in 80% Matrigel/20% ENR media. 
Complete crypt culture (ENR) medium   
Basal culture medium  -add to final volume  23 mL 
mEGF (500 ug/mL)                final= 50 ng/mL  2.5 µL 
0.5 M N-acetylcysteine  final= 1 mM   50 µL 
N2 Supplement (100x) final= 1x   250 µL 
B27 Supplement (50x) final= 1x   500 µL 
293TCT-NtRiP CM (~20x) final=5%   1.25 mL 
 
Basal culture medium 
 
Advanced DMEM/F12 + 2 mM Glutamax + 10 mM HEPES + 1% P/S 
 
Adenoviral-Cre mediated infection 
Adenovirus Cre recombinase-mCherry was obtained from the University of Iowa (Ad5CMVCre-
mCherry) and obtained at stock concentration of 5 x 1010 pfu/ml). Adenovirus was added to 
freshly isolated crypts suspended in 250 µL of 80% Matrigel/ 20% ENR (EGF, Noggin, R-
spondin,). The final concentration of virus used was 2.4 x 108 pfu/mL. Organoids were seeded in 
a 6 well plate and overlayed with 2 mL of ENR media. mCherry fluorescence was detected 72 
hours after infection using a fluorescence microscope. 
Immunofluorescence  
Organoids were seeded in 3 wells of a 12 well plate and grown for 5 days in ENR media. The 
organoids were fixed in 1 mL of 10% buffered formalin for 1 hour at 4°C. The organoids were 
scraped from each well and dissociated using Cell Recovery Solution (Corning) at 4° for 30 
minutes on a rotator and transferred to 1.5 mL Eppendorf tubes. The organoids were blocked for 
1 hour in blocking solution overnight at 4° (5% goat serum, 0.5% Triton-x 100 in PBS). 
Organoids were incubated for 1 hour with primary antibodies (rabbit HER2, Cell signaling, 
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29D8) in blocking solution. Organoids were then washed three times with PBS and incubated 
with the secondary antibody (Alexa Fluor 488, Goat anti-rabbit, Thermo Fisher) for 4-5 hours at 
room temperature. Lastly, organoids were incubated with DAPI for nuclear staining (1:1000, 
Thermo Fisher). This protocol is adapted from Strubberg et al (83). 
Fixed frozen sections of intestinal organoids 
Organoids were grown in 3 wells of a 12 well-plate, scraped and dissociated using Cell Recovery 
solution (Corning) for 30 minutes at 4°C and transferred to 1.5 mL Eppendorf tubes. Organoids 
were incubated in 1 mL of 4% PFA overnight. After removing the PFA, 1 mL of 10% sucrose 
(Sigma) was added to each Eppendorf tube containing the organoids. The sucrose solution was 
removed and replaced with fresh sucrose after 4 hours, and organoids were spun down at 300 
rpm. OCT (VWR) was added to each organoid pellet after removing the sucrose solution, and the 
OCT/organoid mixture was added to a cryomold block. Blocks were stored at -80°C until 
sectioning. Sections were made on a cryostat and placed on uncharged slides for 
immunohistochemistry. 
Immunohistochemistry of fixed frozen sections 
For histology, unstained slides were stained for the indicated antibodies via 
immunohistochemistry (Department of Immunology and Pathology, Washington University 
School of Medicine). Immunohistochemistry was performed by a standard protocol on Ventana 
automated stainer (Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was 
performed for for KI-67 2 ug/mL (rabbit monoclonal, clone 30-9)(Ventana) with CC1 buffer 
(Cell Conditioning 1; EDTA-based buffer pH 8.0, Ventana). 
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Isolation of organoid lysates and western blotting 
Organoid lysates were prepared as follows: Organoids were seeded in 3 wells of a 12 well plate 
and grown in ENR media for 5 days. Organoids were scraped from the 12 well plate and 
dissociated with 1 mL of Cell Recovery solution (Corning) for 30 minutes at 4°C. Organoids 
were spun down at 500 x g, re-suspended in 50 uL of RIPA buffer, and sonicated for 90 seconds. 
Lysates were spun down at 13,000 rpm for 5 minutes and the supernatant was transferred to a 
new Eppendorf tube. Lysates were boiled for 5 minutes at 95°C and stored in -20. Western 
blotting was performed as described (37). 
Quantitative Reverse Transcription (RT)-PCR (qRT-PCR) 
RNA was isolated from intestinal organoids and 2 ug of RNA were reverse transcribed into 
cDNA using the cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). qRT-
PCR was performed with a ABI Prism 7300 Sequence Analyzer using SYBR green fluorescence 
probes. Quantification cycle (Cq) of genes of interest were normalized to the average Cq of actin 
and expressed as relative mRNA levels. Primer sequences are listed below (5’ to 3’). 
Primer name                          Primer sequence 
c-Myc F   CACACAACGTCTTGGAACGT 
c-Myc R   CGTCTGCTTGAATGGACAGG 
Actin F   TTGCTGACAGGATGCAGAAG 













HER2 and APC mutations activate downstream signaling pathways and confers 
morphological changes 
To determine the role of HER2V777L expression on downstream signaling pathways and overall 
organoid morphology, we utilized intestinal organoids generated from a HER2V777L transgenic 
(Tg) mouse generated via TALEN based gene editing (Figure 2.1). HER2V777L Tg derived mouse 
organoids were treated with Adenovirus-Cre recombinase (AdCre) to excise the Lox-STOP-Lox 
cassette and induce expression of the transgene. To confirm that HER2 was expressed in our 
organoid cultures, we stained for HER2 via immunofluorescence using a HER2 primary 
antibody and an Alexa Fluor 488 secondary antibody. Immunofluorescence confirmed HER2 
expression in all of the organoid cultures treated with AdCre (Figure 2.2). In contrast, intestinal 
organoid cultures not treated with AdCre possessed low levels of basal HER2 expression. 
Next, we examined signaling pathway changes induced by expression of HER2V777L. We found 
that expression of HER2V777L alone activated phosphorylation of HER2 and downstream 
signaling proteins such as MAPK (Figure 2.3). Additionally, we generated intestinal organoids 
from APCmin and HER2V777L Tg mice double mutant mice (APCmin; HER2V777L Tg), at 16 weeks 
of age from intestinal polyps. Similarly, expression of HER2 in the APCmin; HER2V777L Tg 
organoids also activated phosphorylation of HER2 and MAPK downstream signaling (Figure 
2.3). As a result, we validated our intestinal organoid model and confirmed that expression of 













Figure 2.2 HER2 expression in organoid cultures via immunofluorescence. Organoid lines 
were treated with AdCre and assayed for immunofluorescence one week after infection to detect 





Figure 2.3 Western blot of HER2V777L Tg and APCmin; HER2V777L Tg organoid lysates. 
Western blot analysis of organoids derived from B6 mice (WT) and intestinal organoids treated 
in the presence and absence of AdCre (1 week after infection). 
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HER2V777L expression confers enhanced budding and growth-factor independence 
We next determined whether expression of HER2 or APC mutations alone or in combination 
resulted in morphological changes in the organoid cultures. Expression of HER2V777L alone was 
found to enhance budding of intestinal organoids in EGF, Noggin, R-spondin (ENR) media by 
2.5-fold, relative to organoids that were not treated with AdCre  (non-HER2V777L expressing) 
(Figure 2.4A-B). Furthermore, withdrawal of EGF in the HER2V777L Tg organoids conferred 
growth factor independence in the HER2V777L Tg AdCre treated organoids as observed by 
enhanced organoid budding in EGF-free media relative to ENR media (Figure 2.4A-B). 
Interestingly, expression of both HER2V777L and APC mutations conferred a distinct 
morphological change and APCmin; HER2V777L Tg organoids possessed a 10-fold increase in the 
number of budded structures relative to APCmin only organoids (Figure 2.5A-B). The budded 
structures observed also contrasted the normal cyst-like morphology of APCmin derived 
organoids. 
To determine whether the enhanced budding phenotype observed in the HER2V777L Tg organoids 
was due to increased proliferation, we utilized immunohistochemistry staining for Ki-67. 
HER2V777L expression conferred a rapid budding phenotype with Ki-67 positive cells located 
prominently within each bud (Figure 2.6). Additionally, expression of HER2V777L in the APCmin; 
HER2V777L Tg organoid cultures resulted in expanded proliferation outside of the budded 
regions, which was not observed in control organoids (Figure 2.6). Taken together, HER2V777L 
expression enhances proliferation of intestinal organoid cultures and HER2 and APC mutations, 









Figure 2.4 Morphology of HER2V777L Tg organoids (A) Brightfield images of HER2V777L Tg 
intestinal organoids grown in ENR media and media lacking EGF for 5 days. (B) Quantification 
of average number of buds per organoid in ENR and no EGF media. Scale bars are 500 µm. 
Representative data from 3 independent experiments. ∗P < .05; ∗∗P < .01 by one-way ANOVA. 
n.s., not significant. 
 
 
Figure 2.5 Morphology of APCmin; HER2V777L Tg organoids (A) Brightfield images of 
APCmin; HER2V777L Tg organoid cultured in ENR media for 5 days and (B) average number of 
budded or non-cystic structures in APCmin; HER2V777L organoids. Scale bars are 500 µm. 






Figure 2.6 IHC staining for Ki-67 in HER2V777L Tg and APCmin; HER2 Tg organoids. 
Representative images of Ki-67 staining of fixed frozen organoid sections grown in ENR media 
for 4 days. Scale bars are 500 µm. 
Activation of Wnt signaling pathway changes HER2V777L Tg organoid morphology 
Due to the profound budding phenotype observed in the HER2V777L-expressing organoid 
cultures, we assessed whether Wnt activation would revert the observed budding phenotype. The 
intestinal organoids were treated with a GSK-3β inhibitor, Chiron99021, to determine whether 
Wnt activation reduces budding and confers a cyst-like morphology in the HER2V777L Tg 
organoids. Treatment of the organoid lines with 4 uM of Chiron99021 for 3 consecutive passages 
resulted in a 4.6-fold decrease in the number of buds in HER2V777L Tg expressing organoids 
relative to a 5.8-fold change in non-HER2V777L expressing organoids (Figure 2.7A-B). These 
differences were likely due to the enhanced budding phenotype observed in the HER2V777L Tg 
organoid cultures. Additionally, repeated passage of the organoids in media containing 
Chir99021 conferred a cyst-like morphology and the HER2V777L Tg organoids failed to bud in 
this media condition (data not shown).  
Expression of HER2V777L confers resistance to MEK inhibition 
To examine potential mechanisms underlying the enhanced proliferation and budding observed 
in the HER2V777L organoid cultures, we examined cell proliferation changes after treatment with 
a MEK inhibitor, TAK-733. Given the enhanced MAPK signaling observed in the HER2V777L Tg 
expressing cultures, we hypothesized that HER2V777L expression would confer resistance to 
TAK-733. After treatment with TAK-733 for 5 days, HER2V777L Tg AdCre organoids possessed 
decreased drug sensitivity (9.5-fold) relative to non-HER2V777L expressing organoids (Figure 
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2.8). Additionally, APCmin; HER2V777L Tg AdCre organoids possessed a similar sensitivity to 
TAK-733 as HER2V777L Tg AdCre organoids, As a result, we determined that HER2V777L confers 
enhanced growth in a MEK independent manner and other signaling pathways likely contribute 





Figure 2.7 GSK3β inhibitor treatment of HER2V777L Tg and APCmin; HER2V777L Tg 
organoids. (A) Morphology of HER2V777L Tg organoids 5 days after treatment with Chir99021 
and (B) Quantification of average bud number per organoid after Chir99021 treatment. Scale 
bars are 500 µm. Representative data from 3 independent experiments. ∗P < .05; ∗∗∗P < .001 by 





Figure 2.8 TAK-733 dose response of HER2V777L Tg and APCmin; HER2V777L Tg organoids 
Percent cell growth of indicated organoid lines after treatment with TAK-733 for five days as 
measured via alamar blue assay. 
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HER2 and APC mutations enhance activation of Wnt-target genes 
We also sought to examine whether HER2V777L expression conferred enhanced signaling of Wnt-
target genes give the cross-talk associated with EGFR family members and the Wnt-signaling 
pathway (84). Additionally, APC mutations result in beta-catenin translocation to the nucleus 
and expression of Wnt target genes, such as c-Myc (85). Interestingly, expression of HER2V777L 
alone did not confer enhanced expression of c-Myc relative to untreated organoids (Figure 2.9). 
However, c-Myc expression was enhanced by 2-fold in APCmin; HER2V777L Tg AdCre organoids 
relative to organoids only expressing HER2V777L, suggesting a role for HER2V777L expression on 
Wnt signaling pathway activation in the context of APC loss. Overall, we determined that the 
expression of APC and HER2 mutations enhances expression of a Wnt-target gene, c-Myc, as a 
possible mechanism for enhanced growth. Future work will assess RNA expression differences 





Figure 2.9 qPCR analysis of HER2V777L Tg and APCmin; HER2V777L Tg organoid lines 
Relative expression of c-Myc mRNA using RNA isolated from intestinal organoid lines grown in 







Overall, we have determined the role of HER2 and APC mutations on cell proliferation, 
downstream signaling pathways, and cell morphology using an intestinal organoid culture model. 
These studies are the first to illustrate the role of the activating HER2V777L mutation on intestinal 
epithelial proliferation using an intestinal organoids. We determined that HER2V777L expression 
increased budding, enhanced proliferation within budded regions, and conferred resistance to a 
MEK inhibitor, TAK-733 (Figure 2.10).  
Previous studies exploring the role of other EGFR family members, such as HER3, on organoid 
morphology have determined that HER3 knock-out intestinal organoid cultures morphologically 
resemble WT cultures in size, growth rates, and budding rates (86). In contrast, our studies 
illustrate a role for HER2V777L on growth and proliferation, which is observed via enhanced 
budding of our intestinal organoid cultures. Our results suggest that the budding phenotype is 
due to enhanced proliferation and activation of pro-growth signaling pathways. HER2V777L 
expression was also found to confer resistance to MEK inhibitors, which underscores a greater 
need to understand how to best target HER2mutant colorectal cancers.  
We also determined the role of APC and HER2 co-occurring mutations using our intestinal 
organoid culture model. Previous studies have determined that APC and KRAS double mutant 
organoids form cystic structures in culture and form liver metastases when transplanted 
subcutaneously (87).  In our organoid culture model, we determined that APCmin; HER2V777L Tg 
AdCre organoids possessed enhanced budding, expanded proliferation zones, and enhanced c-
Myc expression via qPCR analyses. The abnormal budding phenotype observed in our APCmin; 
HER2 Tg cultures is likely due to increased proliferation conferred by HER2V777L expression. 
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These preliminary studies would also benefit from RNA sequencing analysis to determine which 
genes are upregulated in response to HER2 or APC mutations in our organoid culture model. 
Future work will utilize in vivo models to further determine the impact of HER2 and APC 
mutations on the crypt-villus architecture of the intestinal epithelium and tumorigenesis. Overall, 
we demonstrated an initial characterization of the role of both HER2 and APC mutations and 
































Chapter 3: HER2 and APC mutations promote altered crypt 















This chapter was adapted from: 
Murray E, Krishna A, Ohara T, Stappenbeck T, and Bose R. (2020) HER2 and APC 
mutations promote altered crypt-villus morphology and marked hyperplasia in the 
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Colorectal cancer patients possess co-occurring HER2 and APC mutations. Here, we 
investigated the role of HER2 and APC mutations on the crypt-villus architecture of the 
intestinal epithelium, localization of secretory cells, and expression of intestinal stem cell 
markers. We generated a HER2 transgenic mouse (HER2V777L Tg) possessing an activating 
mutation commonly found in colorectal cancer patients, HER2V777L, using TALEN based gene 
editing technology. We determined that HER2V777L expression resulted in hypertrophic crypt 
formation with expanded zones of proliferation, hyperplasia, and mis-localized Paneth cells. 
Additionally, we determined that HER2 and APC mutations, when combined, promote enhanced 

















The intestinal epithelium is tightly regulated by the expression of several growth factors 
produced within the stem cell niche that control intestinal cell proliferation and differentiation. 
For example, members of the epidermal growth factor receptor family (EGFR, HER2, HER3, 
and HER4) are commonly expressed throughout the intestinal epithelium and regulate cell 
migration, survival, and differentiation (88). Furthermore, overexpression of these receptor 
tyrosine kinases is known to result in poor outcomes in several gastric and other solid tumor 
types (89-90). Further study of these receptor tyrosine kinases is needed to delineate their role in 
cancer development. 
HER2 mutations or alterations are known to have functional significance in colorectal cancer 
development (33). For example, in vitro characterization of HER2 mutations has identified 
several activating mutations, such as V777L and V842I that activate downstream signaling 
pathways in colon cancer cell lines and confer anchorage-independent growth in soft agar assays 
(37). As a result, HER2 mutations are thought to play a crucial role in cancer development, 
however, the precise role that these mutations play on the intestinal epithelium has not been 
determined. 
Prior studies on other EGFR family members, such as HER3, have identified that expression of 
these receptors play crucial roles in wound healing following chemically induced colitis, 
tumorigenesis, and differentiation of secretory cell types, such as Paneth cells (91-93). Paneth 
cells have been identified as crucial for maintenance of the stem cell niche and dysregulation of 
Paneth cells are observed in the inflammatory bowel diseases, which are pre-malignant 
conditions. Although the role of HER3 on the intestinal epithelium is well-defined, the role of an 
activating HER2 mutation on intestinal epithelial architecture has not been characterized. As a 
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result, we sought to determine the role of an activating HER2 mutation, HER2V777L, on the crypt-
villus architecture of the intestinal epithelium. Furthermore, we also sought to examine the role 
of HER2V777L on tumor formation and CRC progression using an APCmin mouse model. 
We demonstrated that in vivo expression of HER2V777L resulted in hyperplasia, expansion of 
intestinal crypts, and mislocalization of Paneth cells. Furthermore, HER2V777L expression, in the 
context of APC loss, further enhanced proliferation of small intestinal crypts. These data provide 
the first test of HER2V777L expression on intestinal epithelial homeostasis and provides further 















Generation of transgenic mice expressing HER2V777L in the intestinal epithelium 
HER2V777L transgenic mice (HER2V777L Tg) were generated using TALEN based genome 
editing. ROSA26 specific TALENs were designed using the ZiFit targeter (94). The TALEN kit 
used for TALEN assembly was a gift from Keith Joung (Addgene kit # 1000000017). DNA 
fragments encoding ROSA TALEN repeat arrays were cloned into plasmid pJDS71. ROSA 
TALENs plasmids were linearized for in vitro transcription with EcoRI and TALENs RNA was 
synthesized using the mMessage mMachine T7 Ultra kit (Ambion) and purified with Megaclear 
columns (Ambion). 
The cassette of interest was synthesized (Genscript) and introduced into the mouse genome via 
pronuclear injection of in vitro transcribed TALENs RNA and ROSA donor DNA. Founders 
with correctly targeting mutant alleles are identified using long PCR with ROSA specific oligos 
outside of the homology arms. Founders are mosaic with multiple mutant alleles and are bred to 
WT to generate heterozygous F1 offspring. Analysis of F1 offspring via long PCR confirms 
germline transmission of the correctly targeted allele. Primers for genotyping heterozygous 
offspring are:  
ROSA-green-WT-F1: 5’ GTT ATC AGT AAG GGA GCT GCA GTG GAG TAG 3’ 
ROSA-green-WT-R1: 5’ CCG AAA ATC TGT GGG AAG TCT TGT CCC TCC 3’ 




Lgr5-Cre ERT2 and Villin-Cre ERT2 mice 
Lgr5-EGFP-Ires-CreERT2 mice were purchased from Jackson Laboratory (B6.129P2-
Lgr5tm1(cre/ERT2)Cle/J; 008875) and Villin-Cre ERT2 mice were a gift from Blair Madison and are 
also available from the DDRCC core (95). APCmin mice were also purchased from Jackson 
Laboratory (C57BL/6J-ApcMin/J; 002020). All animal work was approved by the Washington 
University School of Medicine Animal Studies Committee. 
Induction of recombination 
Expression of the transgene was driven by Cre-recombination of the lox-stop-lox sites. We 
crossed HER2V777L Tg mice to Lgr5-EGFP-IRES-CreERT2 or Villin-CreERT2 mice to activate 
HER2 expression in intestinal stem cells or the intestinal epithelial cells, respectively. To study 
the contribution of APC loss on the intestinal epithelium, Lgr5-Cre; HER2V777L Tg mice were 
crossed with heterozygous APCmin mice to generate Lgr5-Cre; APCmin; HER2V777L Tg mice.  
For CreERT2-mediated recombination, 8-9 week old mice were injected intraperitoneally with 
tamoxifen (2 mg/injection; Sigma-Aldrich, St. Louis, MO) dissolved in corn oil for three 
consecutive days and sacrificed 10 days after the last tamoxifen injection.  
Immunohistochemistry of paraffin-embedded sections 
The proximal small intestine, distal small intestine, and colon were embedded in 2% agar, 
paraffin embedded, and 5 µm sections were prepared (Digestive Diseases Research Core, 
Washington University School of Medicine). For histology, unstained slides were stained for the 
indicated antibodies via immunohistochemistry (Department of Immunology and Pathology, 
Washington University School of Medicine). Immunohistochemistry was performed by a 
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standard protocol on Ventana automated stainer (Ventana Medical Systems, Tucson, AZ, USA). 
Antigen retrieval was performed for HER2 /neu (rabbit monoclonal, clone 4B5) (Ventana) with 
CC1 buffer (Cell Conditioning 1; EDTA-based buffer pH 8.0, Ventana), for KI-67 2 ug/mL 
(rabbit monoclonal, clone 30-9 )(Ventana) with CC1 buffer (Cell Conditioning 1; EDTA-based 
buffer pH 8.0, Ventana) for Lysozyme (rabbit polyclonal) (Cell Marque) with CC1 buffer (Cell 
Conditioning 1; EDTA-based buffer pH 8.0, Ventana). 
Biotin-free multimer technology system, based on direct linkers between peroxidase and 
secondary antibodies (ultraView Universal DAB Detection Kit, Ventana Medical System) were 
used as detection kit. 
Immunofluorescence of paraffin-embedded sections 
Slides were de-paraffinized and subjected to heat-induced antigen retrieval in Trilogy 
(MilliporeSigma) solution for 20min. Slides were blocked in PBS containing 1% BSA, 5% goat 
serum and 0.1% Triton-X 100 for 1hr at room temperature, and then treated with primary 
antibodies at desired dilutions for 16 hours at 4°C. Slides were then washed 3 times in PBS and 
incubated with secondary antibodies conjugated with fluorophores (Thermo Fisher Scientific) for 
1 hour at room temperature (96). 
Establishment of intestinal organoid cultures 
Isolation of crypts from the jejunum of Lgr5-Cre; HER2V777L Tg and HER2V777L Tg littermate 
mice were performed as described (72) and as listed in chapter 2. Isolated intestinal crypts were 
embedded in Matrigel (BD Biosciences) and seeded in 6-well plates. The cells were overlaid 
with 2 mL/well basal culture medium (advanced Dulbecco’s modified Eagle medium/F12 
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supplemented with penicillin/streptomycin, 10 mmol/L HEPES, Glutamax, 1 × N2, 1 × B27 [all 
from Thermo Fisher Scientific], and containing EGF (Sigma), noggin, and Rspo1 (Noggin and 
R-spondin conditioned media were a gift from Blair Madison).  
Transmission Electron Microscopy 
For ultrastructural analyses, samples were fixed in 2% paraformaldehyde/2.5% glutaraldehyde 
(Polysciences Inc., Warrington, PA) in 100 mM sodium cacodylate buffer, pH 7.2 for 2 hr at 
room temperature and then overnight at 4C.  Samples were washed in sodium cacodylate buffer 
at room temperature and postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 hr.  Samples 
were then rinsed extensively in dH20 prior to en bloc staining with 1% aqueous uranyl acetate 
(Ted Pella Inc., Redding, CA) for 1 hr.  Following several rinses in dH20, samples were 
dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.).  
Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., 
Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX 
transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 
megapixel digital camera and AMT Image Capture Engine V602 software (Advanced 
Microscopy Techniques, Woburn, MA).   
Quantitative Reverse Transcription (RT)-PCR (qRT-PCR) 
RNA was isolated from the jejunum of the Lgr5-Cre; HER2V777L Tg mice and 2 ug of RNA were 
reverse transcribed into cDNA using the cDNA reverse transcription kit (Applied Biosystems, 
Foster City, CA). qRT-PCR was performed with a ABI Prism 7300 Sequence Analyzer using 
SYBR green fluorescence probes. Quantification cycle (Cq) of genes of interest were normalized 
to the average Cq of 18s ribosomal RNA (reference gene) and expressed as relative mRNA 
levels. Primers were a gift from Matt Ciorba and primer sequences are listed below (97). 
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Primer name    Primer sequence 
18s F                                                   GTAACCCGTTGAACCCCATT 
18s R     CCATCCAATCGGTAGTAGCG 
mLgr5 F TGCCCATCACACTGTCACTGT 
mLgr5 R CACCCTGAGCAGCATCCTG 
mLrig1 F TTGAGGACTTGACGAATCTGC 
mLrig1 R CTTGTTGTGCTGCAAAAAGAGAG 
mAlpi F AGGACATCGCCACTCAACTC 
mAlpi R GGTTCCAGACTGGTTACTGTCA 
mAtoh1 F GGGGTTGTAGTGGACGAGC 
mAtoh1 R CGTTGTTGAAGGACGGGATAAC 
mMuc2 F ATGCCCACCTCCTCAAAGAC 
mMuc2 R GTAGTTTCCGTTGGAACAGTGAA 
mChgA F CCAAGGTGATGAAGTGCGTC 
mChgA R GGTGTCGCAGGATAGAGAGGA 
mLyz F GAGACCGAAGCACCGACTATG 
mLyz R CGGTTTTGACATTGTGTTCGC 
mDefcr5 F AGGCTGATCCTATCCACAAAACAG 
mDefcr5 R TGAAGAGCAGACCCTTCTTGGC 
mAxin2 F AACCTATGCCCGTTTCCTCT 
mAxin2 R CTGGTCACCCAACAAGGAGT 
mOlfm4 F GCCACTTTCCAATTTCAC 
mOlfm4 R GAGCCTCTTCTCATACAC 
mBmi1 F CCAATGAAGACCGAGGAGAA 
mBmi1 R TTTCCGATCCAATCTGCTCT 
mSI F  GCTATCGCTCTTGTTGTGGTT 
mSI R TTCCAGGACTAGGGGTTGAAG 
mAlpi F AGGACATCGCCACTCAACTC 
mAlpi R GGTTCCAGACTGGTTACTGTCA 
 
Genomic analysis of ERBB2 and APC co-occurring mutations 
Mutations were extracted from TCGA Unified Ensemble MC3 Call Set (98). Colon 
Adenocarcinoma (COAD) or Rectum Adenocarcinoma (READ) patients were extracted from the 
MC3 mutation file resulting in a total of 559 patients with 223860 mutations (excluding the 
following mutation types: Silent, Intron, RNA, 5’ Flank, 3’ flank, IGR, Translation Start Site, 3’ 





Data are presented as means and SEM. The Student t test was used to analyze data with 2 groups. 
For statistical analysis, GraphPad Prism (version 7; GraphPad Software, Inc, La Jolla, CA) was 
used. A P value less than .05 was considered statistically significant. All authors had access to 

















HER2V777L expression driven by Lgr5-CreERT2 enhances crypt depth and villus length 
HER2 transgenic mice expressing the Lox-STOP-Lox HER2 V777L transgene (HER2V777L Tg) 
were generated using TALEN based gene editing (Figure 3.1A). The HER2 V777L mutation is a 
constitutively activated mutation that has been identified in human colorectal cancer patients 
(37). Since colorectal cancer arises from intestinal stem cells, we utilized the Lgr5-CreERT2 
mouse strain, which expresses Cre-recombinase in the Lgr5-positive crypt-base columnar stem 
cells to activate HER2V777L expression (99-100).  
To assess the role of HER2V777L expression on the intestinal epithelium, two-month old Lgr5-
Cre; HER2V777L Tg and littermate control mice were treated with tamoxifen for 3 consecutive 
days and sacrificed 10 days after the last injection (Figure 3.1B). HER2V777L expression resulted 
in hypertrophic crypt formation throughout the proximal small intestine, distal small intestine, 
and colon relative to littermate control mice (Figure 3.1C-E). In the mucosal folds of the 
proximal colon, HER2V777L expression also triggered remodeling of the epithelium with finger-
like projections resembling villi, which were not observed in the colon of control mice (Figure 
3.1E). The observed hypertrophic phenotype was also illustrated by increased crypt depth in 
Lgr5-Cre; HER2V777L Tg mice in the proximal small intestine, distal small intestine, and colon by 
1.4, 1.8, and 2.6-fold, respectively (Figure 3.1F, respectively). HER2V777L expression also 
increased the number of Ki-67 positive cells by 2.2, 1.9, and 1.9-fold in the proximal small 
intestine, distal small intestine, and colon, respectively (Figure 3.1G). Lastly, HER2V777L 
expression also increased villus length in the proximal and distal small intestine by 1.8 and 1.6-
fold, respectively, relative to control mice (Figure 3.1H-I). These findings demonstrate that 
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HER2V777L expression resulted in pronounced hypertrophic crypt formation characterized by 
enhanced proliferation and increased height of intestinal villi. 
Next, to determine whether the enhanced growth phenotype observed in vivo is epithelial cell-
intrinsic or cell-extrinsic, we utilized small intestinal organoid cultures. We generated organoids 
from Lgr5-Cre; HER2V777L Tg mice and observed changes in morphology conferred by 
HER2V777L expression. Lgr5-Cre; HER2V777L Tg organoids possessed larger buds after growth in 
EGF, Noggin, and R-spondin media for 5 days relative to littermate control organoids, which 














Figure 3.1: HER2V777L expression confers hypertrophic crypt formation in vivo and in vitro 
(A) Schematic for design of HER2V777L transgenic mouse. (B) Lgr5-Cre; HER2V777L and 
HER2V777L littermate mice were treated with tamoxifen for 3 consecutive days and sacrificed 10 
days after the last injection. (C-E) H&E, HER2, and Ki-67 images of proximal, distal, and colon 
tissue sections from Lgr5-Cre; HER2V777L Tg and littermate control mice. Scale bars are 50 µm. 
(F) Quantification of crypt depth for proximal small intestine, distal small intestine, and colon as 
measured in micrometers. Eighty crypts per mouse were measured and n ≥ 3 per group. (G) 
Quantification of Ki-67 positive cells per crypt. (H) H&E and HER2 staining of Lgr5-Cre; 
HER2V777L Tg and littermate control villi. Scale bars are 100 µm. (I) Quantification of villus 
length for proximal and distal small intestine. Eighty villi per mouse were measured and n=3 per 
group. (J) Representative image of small intestinal organoids generated from the jejunum of 
Lgr5-Cre; HER2V777L Tg and control mice grown for 5 days in EGF, Noggin, and R-spondin 
media. Scale bars are 500 µm. Data are plotted as means, 1 dot represents 1 mouse and means ± 









HER2V777L expression reduces intestinal stem cell populations and increases expression of 
absorptive markers 
Due to the enhanced crypt size observed in vivo, we next examined whether expression of 
intestinal stem cell markers were altered using qRT-PCR. Expression of the stem cell markers, 
Olfm4, and Lgr5, were reduced by 3.9 and 3.1-fold, respectively, in Lgr5-Cre; HER2V777L Tg 
mice relative to control mice, whereas no significant differences were observed in the expression 
of Lrig, a negative regulator of EGFR signaling. Interestingly, HER2V777L expression increased 
expression of the +4 stem cell marker, Bmi1, by 1.8-fold relative to littermate control mice 
(Figure 3.2A). To determine whether the loss of intestinal stem cells observed was due to 
decreased Wnt signaling, we also examined expression changes of Wnt target genes such as c-
Myc and Axin2 (Figure 3.2B). Although changes in c-Myc expression were not observed, Axin2 
expression was reduced by 2.1-fold in Lgr5-Cre; HER2V777L Tg mice relative to littermate 
control mice. Taken together, our data suggest that HER2V777L expression reduces Wnt signaling 
to decrease the stem cell population in the crypt compartment. The increased expression of 
Bmi1, however, suggests that secretory progenitors are still able to persist. As a result, 
HER2V777L expression enlarges crypt size while reducing the intestinal stem cell population. 
HER2V777L expression promotes enhanced expression of absorptive markers and Paneth 
cell mislocalization 
Given the differences observed in the stem cell population of Lgr5-Cre; HER2V777L Tg mice, we 
next sought to examine whether epithelial differentiation was altered using qRT-PCR. The 
Paneth cell marker, Defcr5, was reduced by 7.3-fold relative to control mice, whereas expression 
of Muc2, a goblet cell marker, was enhanced by 2.9-fold in Lgr5-Cre; HER2V777L Tg mice. 
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Significant differences in Chromogranin A or Lysozyme expression were not observed (Figure 
3.2C). Additionally, expression of Atoh1, a transcription factor required for secretory cell 
differentiation, was not significantly decreased in Lgr5-Cre; HER2V777L Tg mice.  Interestingly, 
expression of the absorptive markers, Fabp1 and Alpi, was increased by 7.6 and 20.9-fold, 
respectively, in Lgr5-Cre; HER2V777L Tg mice (Figure 3.2D). Overall, our data suggests that 
HER2V777L expression promotes goblet cell hyperplasia and enhanced expression of absorptive 




Figure 3.2: HER2V777L expression reduces intestinal stem cell populations and increases 
expression of absorptive markers 
Small intestinal tissue from Lgr5-Cre; HER2V777L Tg and littermate control mice were examined 
for the expression of (A) stem cell markers, (B) Wnt target genes, (C) secretory cell markers, and 
(D) absorptive markers via qRT-PCR. 18s ribosomal RNA was used as a reference gene. n=3 
mice per genotype. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001 as calculated by 











HER2V777L expression promotes Paneth cell mislocalization and goblet cell hyperplasia 
To determine whether the expression changes observed by qRT-PCR could be detected at the 
protein level, we utilized immunohistochemistry to assess Paneth, goblet, and absorptive cells in 
our transgenic mouse model. Paneth and goblet cell number per crypt decreased by 2.6 and 1.5-
fold, respectively, as assessed by Lysozyme and Periodic-Acid Schiff staining, relative to 
littermate control mice (Figure 3.3A and 3.3B-C). Lgr5-Cre; HER2V777L Tg mice also possessed 
a 2-fold increase in enterocytes as assessed by Fabp1 staining (Figure 3.3A and D), which 
correlated with the mRNA expression data shown in Figure 3.2D. Due to the decrease of Paneth 
cells observed in Lgr5-Cre; HER2V777L Tg mice, we assessed structural changes in Paneth cell 
granules using transmission electron microscopy (TEM). For this analysis, we utilized Villin-
Cre; HER2V777L Tg mice due to the mosaicism of the Lgr5-Cre mouse strain. In Villin-Cre; 
HER2V777L Tg mice, Paneth cell granules appeared enlarged and reduced in number via TEM 
relative to littermate control mice (Figure 3.3E).  
Interestingly, although Paneth and goblet cells were reduced per crypt, an increased number of 
Paneth cells were located along the villus instead of the crypt, and goblet cell number per villus 
was increased in Lgr5-Cre; HER2V777L Tg mice by 3 and 1.6-fold, respectively (Figure 3.3F-H). 
Morphologically, the paneth cells observed on the villus resembled goblet cells, indicating that 
these cells may be intermediate cells, possessing both Paneth and goblet cell characteristics. As a 
result, we determined that HER2V777L expression promotes mis-localization of Paneth cells on 





HER2V777L expression down-regulates E-cadherin to promote Paneth cell mislocalization 
Due to the mis-localization of Paneth cells observed in Lgr5-Cre; HER2V777L Tg mice, we sought 
to determine possible mechanisms underlying the observed phenotype. Prior research has shown 
that E-cadherin loss throughout the intestinal epithelium promotes Paneth cell mis-localization 
along the villus (101). Additionally, HER2 expression has been previously shown to down-
regulate E-cadherin expression in breast epithelium (102). As a result, we utilized 
immunofluorescence to determine if E-cadherin expression was decreased in our HER2V777L Tg 
mouse. A reduction in E-cadherin staining along the villus in the Lgr5-Cre; HER2V777L Tg mice 
was observed in contrast to littermate control mice (Figure 3.3I). The pattern of E-cadherin 
staining was also disrupted in Lgr5-Cre; HER2V777L Tg mice. As a result, the Paneth cell mis-











Figure 3.3: HER2V777L expression decreases Paneth cell number per crypt and promotes 
Paneth cell mis-localization  
(A) IHC staining for Lysozyme, Periodic Acid-Schiff (PAS), and Fabp1, respectively of Lgr5-
Cre; HER2V777L Tg and littermate control mice (proximal small intestine). Scale bars are 50 µm. 
(B) Quantification of Paneth cell number per crypt, (C) PAS positive cells per crypt, and (D) 
Fabp1 positive cells per crypt. Eighty crypts were measured from the proximal small intestine 
and n= 3 per group. (E) Transmission electron microscopy (TEM) for Paneth cell granules in 
Villin-Cre; HER2V777L Tg and littermate control mice. Scale bars are 2 µm. (F) IHC staining for 
Lysozyme and PAS on intestinal villi in the proximal small intestine. Scale bars are 100 µm. (G) 
Quantification of Paneth cell number per villus and (H) Quantification of PAS positive cells per 
villus in the proximal small intestine. Eighty intestinal villi were measured and n=3 per group. (I) 
Immunofluorescence staining for E-cadherin in littermate control and Lgr5-Cre; HER2V777L Tg 
mice. Scale bars are 100 µm in left panel and 50 µm in right panel. Representative images are 
shown. Data are plotted as means, 1 dot represents 1 mouse and means ± SEM are reported.  









HER2V777L expression alters Paneth cell granules and adenoma localization  
Next, we sought to examine the role of co-occurring mutations on tumorigenesis using our 
HER2V777L transgenic mouse model. Colorectal cancer patients possessing HER2 missense 
mutations possess several co-occurring alterations in tumor suppressor genes such as APC, 
TP53, and oncogenes such as, KRAS and PIK3CA (98) (Figure 3.4). Of these co-occurring 
mutations, we sought to examine the role of both HER2 and APC mutations on tumor 
progression using an APCmin mouse model. Lgr5-Cre; HER2V777L Tg mice were crossed with 
heterozygous APCmin mice to generate Lgr5-Cre; APCmin; HER2V777L Tg mice and intestinal 
adenomas relative to Lgr5-Cre; APCmin control mice were analyzed via immunohistochemistry 
staining. Surprisingly, HER2V777L expression did not result in significant increases in the number 
of Ki-67 positive cells per adenoma, average adenoma size or adenoma number per mouse 
(Figure 3.5A-D). Interestingly, Lgr5-Cre; APCmin; HER2V777L Tg mice possessed several hyper-
proliferative regions characterized by proliferative crypts that protrude towards villus tips 
(Figure 3.5E). These hyper-proliferative regions were not observed in Lgr5-Cre; APCmin control 
mice. To assess morphological changes in Paneth cells, which are mis-localized throughout 
adenomas, we utilized TEM analysis of Lgr5-Cre; APCmin; HER2V777L Tg mice. TEM identified 
abnormal Paneth cell granules with large vacuoles containing fibrous material, indicating that 
HER2V777L expression may also disrupt Paneth cell morphology (Figure 3.5F). Overall, we 
determined that HER2 and APC mutations promote a hyper-proliferative environment that may 
promote a tumor initiating phenotype rather than tumor progression. Mutations in other tumor 












Figure 3.4-Heat-map of co-occurring mutations in HER2mutant colorectal cancer patients 
Colon Adenocarcinoma (COAD) or Rectum Adenocarcinoma (READ) patients were extracted 
from the TCGA Unified Ensemble call set resulting in a total of 559 patients. All COAD (blue) 
and READ (light blue) patients found to have Missense Mutations in ERBB2 that co-occur with 
any other mutation type in a subset of genes are highlighted on the left. A green box indicates at 
least one mutation was identified in the patient of interest labeled on the x axis. ERBB2 and APC 















Figure 3.5-HER2V777L expression promotes hyper-proliferation in the context of APC loss 
(A) IHC staining for HER2 and Ki-67 in intestinal adenomas of Lgr5-Cre; APCmin; HER2V777L 
Tg and Lgr5-Cre; APCmin mice. Scale bars are 100 µm. (B) Quantification of the average number 
of Ki-67 positive cells per adenoma (proximal and distal small intestine). n=3 per group. (C) 
Average adenoma size per mouse as measured in micrometers (proximal and distal small 
intestine). n≥ 3 per group. (D) Quantification of adenoma number per mouse (proximal and distal 
small intestine). n=3 per group. (E) IHC staining for HER2 and Ki-67 in hyper-proliferative 
crypts. Scale bars are 100 µm. (F) TEM analysis of Paneth cell granules in Lgr5-Cre; APCmin; 
HER2V777L Tg and Lgr5-Cre; APCmin mice. Scale bars are 2 µm in all images except lower right 
(500 nm). Representative images are shown. No significant differences measured by Student t-





This work is the first to characterize the role of HER2V777L expression on the intestinal 
epithelium using transgenic mice. We hypothesized that expression of HER2V777L would promote 
crypt hyperplasia and enhanced proliferation due to the role of HER2 and other EGFR family 
members on cell growth and proliferation using in vitro models (36, 103). Using our transgenic 
mouse model, we determined that HER2V777L expression increased crypt depth and villus height 
via enhanced proliferation (Figure 3.6). Interestingly, HER2V777L expression was also found to 
decrease expression of intestinal stem cell markers, such as Olfm4 and Lgr5. Prior research has 
attributed stem cell loss to decreased expression of Wnt target genes, and a similar phenotype 
was observed in our transgenic mouse model (104). Furthermore, HER2V777L expression also 
resulted in Paneth cell loss per crypt, and Paneth cell loss also likely contributed to the reduction 
of stem cells and Wnt signaling observed, however, further studies are needed to determine the 
underlying mechanism. 
We also assessed the role of HER2V777L expression on secretory and absorptive lineages using 
our transgenic mouse model. Notch signaling is responsible for cell fate determination between 
the absorptive and secretory lineage and hyperactive Notch signaling results in decreased Atoh1 
expression, hyper-proliferation, and increased numbers of enterocytes (105). Interestingly, in our 
HER2V777L Tg mouse model, we did not observe significant differences in Atoh1 expression, 
however, HER2V777L expression promoted goblet cell hyperplasia and increased expression of 
absorptive markers. The secretory and absorptive phenotype observed may be due to hyper-
proliferation in our model, which enhances villus height leading to increased numbers of goblet 
cells and enterocytes. Further analysis of Notch signaling pathway components will be needed to 
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determine the role of HER2V777L expression on secretory cell determination. We also observed a 
striking phenotype in which Paneth cells were mis-localized on the villus and this phenotype was 
likely due to reduction of E-cadherin, which is known to contribute to Paneth cell localization in 
the intestinal epithelium (101). In summary, we determined that HER2V777L expression promotes 
crypt hyperplasia, intestinal stem cell loss, and altered Paneth cell localization (Figure 3.6).  
Limitations to our model include a short time frame (10 days) between the last tamoxifen 
injection and tissue analysis of our Lgr5-Cre; HER2V777L Tg mice. Longer time points following 
tamoxifen injection could examine changes in the observed phenotypes over time. Additionally, 
we acknowledge that our model illustrates overexpression of an activating HER2V777L mutation, 
which could produce severe phenotypes not observed in a knock-in model, however, both 
overexpression of HER2 and HER2 mutations are observed in colorectal cancer patients (37). 
Lastly, our studies to examine the role of HER2 and APC mutations on tumorigenesis illustrated 
that HER2V777L expression lead to a hyper-proliferative phenotype in Lgr5-Cre; APCmin; 
HER2V777L Tg mice. Interestingly, we did not observe an increase in the number or size of 
intestinal adenomas in Lgr5-Cre; APCmin; HER2V777L Tg mice relative to control mice. 
Limitations to our tumorigenesis model include the age of mice and the duration of time between 
tamoxifen injection and analysis of intestinal adenomas. Specifically, Lgr5-Cre; APCmin; 
HER2V777L Tg mice were 9 weeks old at the time of analysis and these mice were sacrificed 10 
days after the last tamoxifen injection. Significant differences in adenoma size and number may 
be observed if the length of time was extended after tamoxifen injection. Additionally, 
expression of our HER2V777L transgene might require additional mutations in tumor suppressor 
genes and oncogenes for progression of benign adenomas to carcinomas. 
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In summary, we determined that HER2V777L expression conferred hypertrophic crypt formation 
and mis-localization of Paneth cells. Expression of both HER2 and APC mutations resulted in 
enhanced proliferation of the crypt compartment (Figure 3.6). This work is the first to 
characterize the role of HER2V777L on the intestinal epithelium and illustrates a critical role for 
HER2V777L in the early stages of tumorigenesis. The striking phenotypes observed using the 
HER2V777L transgenic mouse model also illustrates a need to study the role of oncogenes in early 
cancerous lesions in order to better understand the underlying morphological changes associated 







Figure 3.6-Model of HER2 and APC mutations on the intestinal epithelium 
HER2V777L expression conferred hypertrophic crypt formation characterized by loss of intestinal 
stem cells and mis-localization of paneth cells along the villus. Additionally, HER2V777L 
expression induced goblet cell hyperplasia and increased expression of absorptive cell markers. 














Chapter 4: Functional characterization of co-occurring mutations in 
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4.2 Abstract  
 
In colorectal cancer patients, HER2 mutations confer resistance to a HER2/EGFR tyrosine 
kinase inhibitor, neratinib, whereas HER2 mutant breast cancer patients are sensitive to 
neratinib. Given the lack of response in colon cancer patients, we sought to determine various 
mechanisms of resistance to neratinib, using colorectal cancer cell lines (CW-2 and CCK-81) 
engineered to overexpress hotspot PIK3CA or KRAS mutations. We determined that expression 
of the KRAS G12V mutation in the CW-2 and CCK-81 cells conferred resistance to neratinib 
and enhanced MAPK phosphorylation. In contrast, the PIK3CA mutations did not have effect 
neratinib sensitivity. Lastly, the JVE187 cell line, expressing endogenous HER2, KRAS, and 
PIK3CA mutations, was resistant to neratinib, yet sensitive to PI3K inhibition. Our experiments 
provide initial characterization of the role of co-occurring mutations on sensitivity to HER2 















Mutation or over-expression of colorectal cancer driver genes often results in resistance to 
targeted therapeutics. For example, expression of HER2 kinase domain mutations in colon cell 
lines conferred reduced sensitivity to EGFR inhibitors, such as cetuximab, due to sustained 
MAPK signaling. In contrast, HER2 mutations conferred sensitivity to dual HER2/EGFR 
targeted therapy, such as neratinib in colon cell lines (37). However, a recent basket trial of 
HER2 mutant tumors (breast, lung, colorectal, biliary) treated with neratinib identified tumor 
shrinkage in breast and lung, however, HER2 mutated colorectal cancer patients did not respond 
to neratinib (42). The lack of response observed was attributed to co-occurring mutations in the 
RAS or PI3K signaling pathways and lineage dependent resistance. 
In particular, mutations in KRAS and PIK3CA are known to hyper-activate the Ras/Raf/Mapk 
and Akt signaling pathways, respectively. KRAS mutations, for example, commonly occur at 
codons 12 or 13 (KRAS G12V/G13D), however, exon 4 non-hotspot mutations, such as K117N, 
have also been identified in primary invasive colorectal tumors (106-107). In contrast, mutations 
in PIK3CA are mainly located in the helical domain at codon 545 (exon 9) or the kinase domain 
at codon 1047 (exon 20) in colorectal tumors (108). Previous studies using knock-in gene editing 
of HER2 mutations in breast cancer cell lines have determined that combined expression of 
HER2 and PIK3CA mutations enhances signaling pathway activation and migration (109). 
However, the role of HER2 and co-occurring mutations on neratinib sensitivity using colorectal 
cell lines containing endogenous HER2 mutations has not been determined. As a result, we 




In this study, we determined the effect of mutations in common oncogenes, KRAS and PIK3CA 
in the colorectal cancer cell lines, CW-2 and CCK-81, containing endogenous HER2 mutations. 
We demonstrate that expression of a hotspot KRAS mutation decreased sensitivity to neratinib 
and enhanced MAPK phosphorylation, whereas expression of a non-hotspot KRAS mutation 
only conferred a modest effect in neratinib sensitivity. In contrast, PIK3CA mutations in our 
colon cancer cell lines did not affect neratinib sensitivity. Lastly, we determined that the JVE187 
cell line was resistant to neratinib and not dependent on HER2 expression for growth. These data 
provide a possible rationale for the use dual-targeted therapy in HER2 mutated colorectal cancer 


















Antibodies and Inhibitors  
Antibodies for Western blots were purchased from Cell Signaling Technologies: phosphoEGFR 
(Tyr1173), EGFR, phosphop44/42 MAPK (Thr202/Tyr204), p44/42 MAPK, phosphoAKT 
(Ser473), and AKT; Millipore: phosphoHER2 (pY1248); and Thermo Fisher: HER2 antibody 
(Ab-17). Neratinib was provided by Puma Biotechnology, Inc., under a Materials Transfer 
Agreement. BEZ-235 and ONT-380 were obtained from SelleckChem. 
Cell Lines 
The CW-2 cell line was obtained from Riken BioResource Center and cultured in RPMI 1640 
medium and supplemented with 10% FBS and 1% pencillin/streptomycin (P/S). The CCK-81 
cell line was obtained from JCRB Cell Bank and cultured in EMEM supplemented with 10% 
FBS and 1% pencillin/streptomycin (P/S). Both cell lines were maintained in a 5% 
CO2 humidified atmosphere at 37 °C. The JVE187 cell line was obtained via Materials Transfer 
Agreement from Tom Van Wezel in the Netherlands. JVE187 cells were cultured in RPMI-1640 
supplemented with 10% FBS, 2 mM Glutamax-I, 50 U penicillin and 50 μg streptomycin per mL 
(all from Life Technologies, Grand Island, NY, USA). Cells were cultured at 37°C.  
Alamar blue assays 
Inhibition of cell growth by neratinib, lapatinib, ONT-380, and BEZ-235 was measured by 
Alamar blue assay (36). IC50 values were calculated by a 4 parameter nonlinear regression 




Cloning and Retroviral Transduction of KRAS and PIK3CA Mutants in Colorectal Cancer 
Cell Lines 
The KRAS G12V plasmid was obtained from Addgene (pBabe-Puro-Kras*G12V) and site-
directed mutagenesis was utilized to generate the KRAS K117N mutant. PIK3CA E545K and 
PIK3CA H1047R plasmids were also obtained from Addgene (16642 and 16639). The PIK3CA 
constructs were cloned into the pCFG5 retroviral vector, which contains a zeocin resistance 
marker and an IRES-GFP sequence, using the In-Fusion HD cloning system kit (Clontech, 
Mountain View, CA).The desired constructs were verified using Sanger sequencing. Retroviral 
particles were produced using φNX amphotrophic packaging cell line. PIK3CA or KRAS mutant 
recombinant retroviral supernatants were transduced in CW-2 and CCK-81 cell lines as 
described previously (37). Cell lines were subjected to 1-2 weeks of puromycin selection (KRAS 
cell lines) or zeocin selection (PIK3CA cell lines) and transgene expression was verified by 














Expression of PIK3CA E545K and H1047R mutations in CRC cell lines does not affect 
neratinib sensitivity 
Colorectal patients possess co-occurring mutations in HER2, KRAS, and PIK3CA, which often 
results in poor sensitivity to targeted therapeutics (Figure 4.1). To determine the effect of co-
occurring mutations on neratinib sensitivity using an in vitro model, we introduced the PIK3CA 
E545K and H1047R mutations into the CW-2 cell line. This cell line contains an endogenous 
HER2 L755S mutation as well as other mutations as listed in Table 4.1. We measured the effect 
of these mutations on downstream signaling pathways and sensitivity to neratinib. The 
aforementioned PIK3CA mutations were stably introduced into the CW-2 cells using a retroviral 
vector. The introduction of the PIK3CA E545K mutation enhanced Akt phosphorylation and did 
not affect phosphorylation of HER2 or HER3. The PIK3CA H1047R mutation modestly 
enhanced Akt phosphorylation, and also did not alter phosphorylation of upstream receptors 
(Figure 4.2A). Additionally, expression of either PIK3CA mutation did not alter sensitivity to 
neratinib relative to the CW-2 parental cell line (Figure 4.2B). Overall, introduction of the 
PIK3CA E545K or H1047R mutation primarily activates the Akt signaling pathway and as a 
result, does not impact sensitivity to a HER2 targeted therapeutic. Our in vitro studies also 
illustrate that the E545K mutation has a stronger effect on Akt phosphorylation than the H1047R 









Figure 4.1 Summary of HER2 and co-occurring mutations in colon cancer patients. 
Oncoprint of missense mutations (green) from 18 colorectal cancer patients/samples from the 










Figure 4.2 Neratinib sensitivity of CW-2 PIK3CA cell lines. (A) Western blot analysis of CW-
2 parental (control), CW-2 PIK3CA H1047R, and CW-2 PIK3CA E545K cell lines after 
treatment with increasing doses of neratinib and (B) percent cell growth of CW-2 PIK3CA 
mutant cell lines after treatment with neratinib for 6 days as measured via alamar blue assay. 
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Introduction of a hotspot KRAS mutation decreases sensitivity to neratinib and gefitinib in 
CRC cell lines 
To explore the role of KRAS mutations on neratinib sensitivity using our colon cell line model, 
we introduced the hotspot KRAS G12V mutation and non-hotspot KRAS K117N mutation into 
the CW-2 and the CCK-81 cell lines using a retroviral vector. The CW-2 and CCK-81 cell line 
express endogenous HER2 L755S and L720P mutations, respectively, and Kloth et al has shown 
sensitivity of these cell lines to neratinib (39). The KRAS G12V mutation has been extensively 
characterized as a gain-of-function mutation, whereas the KRAS K117N mutation has been 
identified as a non-hotspot mutation that activates Ras-GTP, albeit to a lesser extent than hotspot 
mutations (107).  
Expression of the hotspot KRAS mutation, G12V, in the CW-2 cell line enhanced 
phosphorylation of MAPK relative to the parental cell lines (Figure 4.3A). Additionally, HER2 
phosphorylation was sustained after treatment with 100 nM neratinib in the KRAS G12V mutant 
cell line. In contrast, expression of the KRAS K117N mutation resulted in a modest increase in 
MAPK phosphorylation relative to CW-2 parental cells. Additionally, the introduction of the 
KRAS G12V mutation resulted in a 5-fold change in neratinib sensitivity relative to CW-2 
parental cells (Figure 4.3B) as measured by alamar blue assay. Expression of the KRAS K117N 
mutation, however, did not change neratinib sensitivity. 
Similarly, introduction of the KRAS G12V mutation in the CCK-81 cells enhanced MAPK 
phosphorylation and mutant cells also possessed residual MAPK phosphorylation at high 
neratinib concentrations, suggesting a potential resistance mechanism (Figure 4.4A). 
Additionally, expression of the KRAS G12V and K117N mutation in the CCK-81 cell line 
resulted in a 6 and 2.4-fold shift, respectively, in the neratinib IC50 (Figure 4.4B). Lastly, we also 
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sought to determine the effect of KRAS mutations on sensitivity to gefitinib, an EGFR inhibitor. 
We hypothesized that due to hyper-activation of downstream signaling pathways, KRAS mutant 
cell lines would confer resistance to gefitinib. Expression of KRAS G12V or KRAS K117N 
mutations conferred modest changes in gefitinib sensitivity (<2-fold) (Figure 4.5A). In contrast, 
expression of KRAS G12V in the CCK-81 cell line conferred an 18-fold change in gefitinib 
sensitivity relative to parental cells, whereas the expression of KRAS K117N conferred a 5.6-
fold change in sensitivity (Figure 4.5B). As a result, we determined that cell lines expressing 
both HER2 and KRAS mutations also confer resistance to EGFR targeted therapeutics.  
A CRC cell line derived from a liver metastasis is resistant to neratinib 
We also assessed the sensitivity of another colorectal cancer cell line, JVE187, containing an 
endogenous HER2 V842I mutation to neratinib. This cell line was of interest due to the presence 
of endogenous co-occurring KRAS and PIK3CA mutations. As listed in table 4.1, this cell line 
possessed the non-hotspot mutations, KRAS K117N as well as PIK3CA Q546K. Treatment of 
the JVE187 cell line with increasing doses of neratinib did not impair cell growth with an IC50 
greater than 250 nM (Figure 4.6A). Treatment of the JVE187 cells with other HER2 targeted 
therapies such as lapatinib and ONT-380 also resulted in resistance. In contrast, JVE187 cells 
were sensitive to PI3K inhibition with BEZ-235, which suggests that these cells were dependent 
on PI3K for growth (Figure 4.6B). Overall, co-occurring mutations likely conferred resistance to 
neratinib in the JVE187 cell line, however, further studies are needed to determine the 











Figure 4.3 Neratinib sensitivity of the CW-2 KRAS G12V and KRAS K117N cell lines. (A) 
Western blot of CW-2 parental, CW-2 KRAS G12V, and CW-2 KRAS K117N cell lines after 
treatment with increasing doses of neratinib and (B) percent cell growth of CW-2 KRAS mutant 







Figure 4.4 Neratinib sensitivity of the CCK-81 KRAS G12V and KRAS K117N cell lines. 
(A) Western blot of CCK-81 parental, CCK-81 KRAS G12V, and CCK-81 KRAS K117N cell 
lines after treatment with increasing doses of neratinib and (B) percent cell growth of CCK-81 
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Figure 4.5 Sensitivity of CW-2 KRAS mutant cell lines to gefitinib. (A) Dose response assays 
of CW-2 KRAS mutant cell lines and (B) CCK-81 KRAS mutant cell lines after treatment with 








Figure 4.6 Response of JVE187 cell line to HER2 targeted therapeutics. (A) Percent cell 
growth of JVE187 cell line after treatment with neratinib and (B) Lapatinib, ONT-380, and BEZ-








A recent basket trial on HER2 mutant cancers determined that HER2 mutant colon tumors were 
resistant to HER2-targeted therapies, such as neratinib (42). Prior studies examining the effect of 
HER2 amplification and co-occurring mutations in colon cell lines have determined that HER2 
amplification confers resistance to EGFR monoclonal antibodies, whereas HER2 amplification 
and PIK3CA mutations, when combined, confer sensitivity to MEK and PI3K combination 
therapy (110). However, in vitro studies exploring endogenous HER2 mutations, instead of 
HER2 amplification, and potential mechanisms of resistance in colon cell lines have not been 
determined.  
Here, we utilize a cell culture model to demonstrate the effect of HER2 and co-occurring 
mutations on sensitivity to HER2 targeted therapy. Using colon cancer cell lines, we determined 
that PIK3CA mutations in either the helical or kinase domain do not alter sensitivity to neratinib 
and do not effect phosphorylation of upstream receptors. Prior studies in breast cancer cell lines 
have also determined that the expression of HER2 and PIK3CA mutations do not change 
sensitivity to a HER2 tyrosine kinase inhibitor, lapatinib, and confirm our results (109). PIK3CA 
mutations likely primarily effect the Akt signaling pathway and do not alter expression of HER2 
or HER3.  
In contrast, we show that introduction of a hotspot KRAS mutation, G12V, decreases sensitivity 
to neratinib in two colorectal cancer cell lines, CW-2 and CCK-81, expressing endogenous 
HER2 mutations. In general, similar effects of the KRAS G12V mutation on neratinib sensitivity 
were observed in the CW-2 and CCK-81 cell lines. Potential mechanisms underlying the 
resistance observed include sustained activation of MAPK signaling after treatment with 
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neratinib or up-regulation of HER2 or HER3 receptors as observed by western blot, however, 
additional experiments need to be conducted to determine a precise mechanism. Additionally, we 
also determined the role of a non-hotspot mutation, KRAS K117N, which has not been 
extensively characterized, on sensitivity to HER2 or EGFR inhibitors. Prior research has 
determined that this mutation enhances MAPK phosphorylation to similar levels observed in 
hotspot mutations (107). We determined that expression of KRAS K117N conferred reduced 
sensitivity to neratinib and gefitinib in the CCK-81 cell line, indicating that this mutation has 
functional significance in our cell culture model. Lastly, we assessed the sensitivity of JVE187, a 
cell line expressing HER2, KRAS, and PIK3CA endogenous mutations to HER2-targeted 
therapies. The JVE187 cell line was resistant to neratinib, and the resistance observed in this cell 
line was likely due to the presence of co-mutations in CRC driver genes. 
Potential limitations of this study include the following. First, retroviral transduction of the 
KRAS mutations into the CRC cell lines can produce overexpression of KRAS. However, 
western blot analysis of total Ras protein levels relative to parental cells indicates the level of 
overexpression is relatively modest in this system (data not shown). Second, we acknowledge 
that other studies have examined the role of acquired KRAS mutations on sensitivity to EGFR 
therapeutics in cell lines lacking HER2 mutations, however, this study examines the role of 
HER2 and co-occurring mutations in colorectal cell lines. Lastly, we acknowledge that future 
studies could benefit from in vivo xenograft assays to determine whether HER2 and KRAS 
mutations enhance tumor formation. 
In summary, this data suggests that patients possessing both HER2 and KRAS mutations could 
benefit from therapies that target HER2 and MEK signaling due to the intracellular signaling 
observed after treatment with neratinib. This work represents an initial characterization of the 
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5.1 Conclusion and Future Perspectives 
The role of EGFR family of receptor tyrosine kinases on cancer development and progression 
has been well studied. EGFR family members are expressed throughout the intestinal epithelium 
and promote growth, proliferation, and maintenance of the intestinal stem cell niche. While prior 
studies have examined the role of EGFR, HER3, and HER4 on proliferation, migration, and 
Paneth cell development, the role of activating HER2 mutation, HER2 V777L, has not been 
previously characterized in the intestinal biology field. In this work, we provide data that 
enhances our understanding of HER2V777L expression on the intestinal epithelium, particularly, 
the impact on intestinal cell proliferation and expression of secretory cells. In addition, we also 
provide initial characterization of the role of HER2 and APC mutations on tumorigenesis.  
We provide the first characterization of an activating HER2 mutation using various in vitro and 
in vivo models. In chapter 2, we utilized an intestinal organoid culture model to examine the 
effect of HER2 and APC mutations, alone or in combination, on organoid morphology, 
intracellular signaling pathways, and expression of Wnt-target genes. Prior studies have 
determined that expression of EGF in intestinal organoid culture media promotes enhanced 
growth, however, studies of an activating HER2 mutation have not been published. Our results 
suggest that expression of HER2V777L enhances budding of intestinal organoid cultures in an 
EGF independent manner and combined mutation of HER2 and APC confers a budding 
phenotype and activation of Wnt-target genes. These studies are crucial in further understanding 
the role of HER2 and APC mutations on intestinal epithelial biology and their role in CRC 
development.  
The results generated from the intestinal organoid model represent an initial characterization of 
HER2V777L expression on the intestinal epithelium, however, several questions remain 
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unanswered regarding the phenotypes observed. First, the enhanced organoid budding due to 
HER2V777L expression was hypothesized to be due to enhanced proliferation. However, the 
specific genes underlying the enhanced growth phenotype have not been determined. RNA-
sequencing analysis of intestinal organoid cultures would therefore determine which genes in 
several pathways are up or down-regulated as a result of HER2 and APC mutations. 
Furthermore, it remains unclear whether the phenotypes observed are specific to the HER2 
V777L mutation or represent a general effect of HER2 overexpression. Prior studies have not 
examined the effect of different HER2 mutations, and additional in vitro studies using CRISPR 
could aid in the understanding of how different mutations impact cell proliferation and 
intracellular signaling pathways in an organoid culture model. Lastly, it remains undetermined if 
HER2 and APC mutations, alone or in combination promote tumorigenesis in our organoid 
culture model. Although HER2 expression in the context of APC loss, conferred increased 
proliferation, it remains unclear if enhanced proliferation is sufficient for tumor formation. To 
address this, future xenograft studies of HER2V777L and APCmin; HER2V777L organoid cultures 
into nude mice would be helpful in examining tumor forming ability. 
A main criticism of this work is the physiological relevance of HER2V777L expression levels in 
our intestinal organoid model. In our model, human HER2V777L is overexpressed under the 
control of a CAG promoter, which is known to result in high expression levels of the transgene. 
We utilized this promoter to ensure that the transgene would be ubiquitously expressed in our 
intestinal organoid model. In order to determine physiological relevance of our model, future 
studies could compare expression of HER2V777L in our model to human colon tumor specimens 
expressing HER2V777L to determine if expression levels are comparable. Additionally, human 
colorectal cancer patients are known to possess both overexpression and mutation of HER2, 
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which our mouse-derived organoid model depicts. Overall, the studies presented in chapter 2 
delineate the role of HER2 or APC mutations on intestinal organoid growth and intracellular 
signaling pathways.  
Next, in chapter 3, we further explored the role of HER2 and APC mutations on the crypt-villus 
architecture of the intestinal epithelium using our HER2V777L transgenic mouse model. In vivo 
expression of HER2V777L, resulted in hyperplasia throughout the small intestine and colon, mis-
localization of Paneth cells, and decreased expression of stem cell marker genes. Furthermore, 
expression of HER2 and APC mutations, in combination, resulted in enhanced crypt 
proliferation, however, adenoma size or number was not impacted. This work was crucial in 
identifying a role of the activating HER2 V777L mutation on intestinal epithelial proliferation, 
however, several questions regarding potential mechanisms remain unanswered.  
First, the mechanism underlying the enhanced proliferation and hyperplasia has not been 
determined. Future studies will utilize immunoblotting and RNA-sequencing analysis to identify 
precise proteins and signaling pathways, such as Ras/MAPK or PI3K/Akt that are up-regulated 
due to HER2V777L expression. Secondly, the phenotypes observed in vivo, such as loss of Paneth 
cells, have not been re-capitulated using intestinal organoid cultures. As a result, future studies 
will utilize immunofluorescence and qPCR analyses to determine if Paneth cell loss, intestinal 
stem cell loss, and hyper-proliferation are also observed in intestinal organoid cultures. Small 
intestinal organoid cultures will also be utilized to determine whether the Wnt or Notch signaling 
pathways are up-regulated as a potential mechanism. Lastly, our model predominately illustrates 
the role of HER2V777L on the small intestine, however, the HER2 V777L mutation is observed in 
colorectal cancers. To increase the relevance of our model for colon cancer, future studies will 
utilize mouse colon tissues derived from our HER2V777L transgenic mouse to examine the effect 
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of HER2V777L expression on proliferation and crypt-depth in the colon. Furthermore, colon 
organoids will also be generated from our HER2V777L transgenic mouse model to elucidate the 
role of HER2V777L expression on organoid morphology, proliferation, secretory cell localization, 
and expression of Wnt and Notch target genes. The addition of these studies will help to further 
elucidate mechanisms responsible for the phenotypes observed in our Lgr5-Cre; HER2V777L Tg 
mouse model. 
Lastly, in chapter 4, we explored the role of co-occurring mutations on sensitivity to HER2-
targeted therapeutics using colon cell lines. Resistance to targeted therapeutics is known to be 
mediated by the expression of oncogenic mutations or upregulation of receptors resulting in 
hyper-activation of signaling pathways. Our data suggests that expression of HER2 and KRAS 
mutations confer resistance to neratinib, a HER2/EGFR tyrosine kinase inhibitor via activation 
of the MAPK signaling pathway. The data presented in this chapter confirm prior research of the 
role of hotspot KRAS or PIK3CA mutations in breast cancer cell lines on sensitivity to HER2 
targeted therapies. Our results also suggest that in addition to the known role of common KRAS 
mutations, that non-hotspot mutations also confer reduced sensitivity to gefitinib and neratinib in 
the CCK-81 cell line. Furthermore, characterization of the JVE187 cell line, a colon cancer cell 
line with several endogenous oncogenic mutations, revealed that multiple non-hotspot co-
occurring mutations impact sensitivity to HER2-targeted therapies. As a result, oncogenic 
mutations, even at non-hotspot regions, impact cell response to therapeutics. To further elucidate 
possible resistance mechanisms, future studies could also utilize transcriptomic analysis or RNA 
expression analyses to uncover signaling pathways differentially effected by HER2 and KRAS 
mutations alone or in combination. The main limitation of our model is the use of retroviral 
transduction to introduce oncogenic mutations. These studies serve as an initial characterization 
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of HER2 and co-occurring mutations, however, additional studies could utilize CRISPR to 
generate genetically edited cell lines, which would result in a more physiologically relevant 
model.  
Overall, the work presented in this thesis, particularly in chapters 2 and 3, further elucidates the 
role of an activating HER2 mutation, HER2 V777L, on the homeostasis of the intestinal 
epithelium. Historically, EGFR family members are believed to not be essential for intestinal 
homeostasis due to receptor redundancy. Instead, these receptors are thought to primarily play a 
role during tumor progression. Interestingly, our work provides evidence for the first time that 
expression of HER2V777L alters intestinal homeostasis by increasing intestinal epithelial cell 
proliferation and enhancing crypt depth and villus height. In addition, this work also further 
enhances our understanding of the contribution of co-occurring alterations on crypt proliferation, 
which provides insight into changes that the intestinal epithelium may undergo prior to tumor 
growth and progression. In summary, the studies presented here significantly enhance the current 
understanding of the role of HER2V777L expression on the intestinal epithelium and the intestinal 
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